Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery Systems

Background:

• Lipid-based nanoparticles (LBNPs) are effective biocompatible drug delivery platforms.
• LBNPs are widely used for genetic therapeutics, particularly nucleic acids, for treating diseases like cancer and viral infections.
• Despite advantages, extracellular and intracellular barriers limit LBNP efficacy.

Purpose of the Study:

• Summarize current knowledge and pitfalls in LBNP gene delivery and construction.
• Review modification strategies to develop next-generation LBNPs.
• Discuss recent advances and challenges in LBNP development for nucleic acid-based immunotherapy.

Main Methods:

• Literature review of LBNP construction and modification strategies.
• Analysis of LBNP performance in various therapeutic applications, especially immunotherapy.
• Identification of remaining challenges in LBNP development.

Main Results:

• LBNPs show promise for treating cancers and infectious diseases via immunotherapy.
• Modifications have improved LBNP delivery profiles and therapeutic effects.
• Key limitations include poor endosomal escape, aggregation, and inefficient therapeutic encapsulation.

Conclusions:

• LBNPs are promising nanoplatforms for nucleic acid-based immunotherapy.
• Further research is needed to overcome barriers like endosomal escape and aggregation.
• Optimizing LBNP design is crucial for enhanced therapeutic outcomes in immunotherapy.